Zidovudine Concentration in Brain Extracellular Fluid Measured by Microdialysis: Steady-State and Transient Results in Rhesus Monkey

ELIZABETH FOX, PETER M. BUNGAY, JOHN BACHER, CYNTHIA L. MCCULLY, ROBERT L. DEDRICK, and FRANK M. BALIS

Pharmacology and Experimental Therapeutics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute (E.F., C.L.M., F.M.B.); Drug Delivery and Kinetics Resource, Division of Bioengineering and Physical Science (P.M.B., R.L.D.); and Surgery Service, Veterinary Resources Program, Office of Research Services, National Institutes of Health, Bethesda, Maryland (J.B.)

Received January 9, 2002; accepted February 11, 2002 This article is available online at http://jpet.aspetjournals.org

ABSTRACT

We measured zidovudine concentrations in blood, muscle, and brain extracellular fluid (ECF) by microdialysis and in serum ultrafiltrate and cerebrospinal fluid (CSF) samples during a continuous intravenous infusion (15 mg/kg/h) and after bolus dosing (50–80 mg/kg over 15 min) in nonhuman primates to determine whether CSF drug penetration is a valid surrogate for blood-brain barrier penetration. Recovery was estimated in vivo by zero net flux for the continuous infusion and retrodialysis for the bolus dosing. In vivo recovery was tissue-dependent and was lower in brain than in blood or muscle. Mean (±S.D.) steady-state blood, muscle, and brain zidovudine concentrations by microdialysis were 112 ± 63.8, 105 ± 51.1, and 13.8 ± 10.4 μM, respectively; and steady-state serum ultrafiltrate and CSF concentrations were 81.2 ± 40.2 and 14.1 ± 8.0 μM, respectively. Brain ECF penetration (microdialysis brain/blood ratio) and CSF penetration (standard sampling CSF/serum ratio) at steady state were 0.13 ± 0.06 and 0.17 ± 0.02, respectively. With bolus dosing the mean (±S.D.) zidovudine area under concentration-time curve (AUC) normalized to a dose of 80 mg/kg was 577 ± 103 μM · h in blood, 528 ± 202 μM · h in muscle, and 108 ± 74 μM · h in brain (brain/blood ratio of 0.18 ± 0.10) by microdialysis. Serum ultrafiltrate AUC was 446 ± 72 μM · h and the CSF AUC was 123 ± 4.7 μM · h (CSF/serum ratio of 0.28 ± 0.06). In conclusion, recovery was tissue-dependent. CSF and brain ECF zidovudine concentrations were comparable at steady state, and the corresponding AUCs were comparable after bolus injection. Thus, zidovudine penetration in brain ECF and CSF in nonhuman primates is limited to a similar extent, presumably by active transport, as in other species.

The intensity of a drug’s pharmacological effect is determined, in part, by the free drug concentration at the effect site in tissues. Pharmacokinetic compartmental modeling may be used to simulate drug concentration in a peripheral compartment. This compartment does not correspond to a particular anatomical space. Its concentration represents appropriately averaged concentrations in all of the tissues contributing to the compartment and may not reflect the concentration in the target tissue(s). For zidovudine in the monkey, the peripheral compartment is expected to be dominated by muscle. Measuring tissue drug concentration directly by biopsy can only provide data at discrete time points and represents total drug concentration in tissue and blood perfusing the tissue. Microdialysis is a minimally invasive tissue sampling technique that can be used for continuous in vivo monitoring of free drug concentration in tissue extracellular fluid (ECF) (Muller et al., 1991; Elmquist and Sawchuk, 1997; Johansen et al., 1997; Davies, 1999).

The microdialysis probe (Fig. 1), which is inserted into tissue, has a semipermeable dialysis membrane at its tip. A solution (perfusate), such as Ringer’s lactate, is continuously infused into the probe and collected from the outflow tube (dialysate). Drug sampling by microdialysis relies on diffusion of drug across the probe membrane driven by the difference in free concentration between the ECF and the dialysate flowing along the inside surface of the membrane. Transit time of the dialysate from the inlet to outlet ends of the membrane is typically too brief to permit equilibration with surrounding tissue. Thus, the drug concentration ([drug]) in the effluent dialysate is related to the [drug] in the ECF, but the concentrations are generally significantly different (Benveniste and Huttemeier, 1990; Bungay et al., 1990; Morrison et al., 1991).

The relationship between ECF [drug] and [drug] in the effluent dialysate is expressed by the recovery or extraction fraction. Accurate estimation of recovery is critical to quan-

ABBREVIATIONS: ECF, extracellular fluid; [drug], drug concentration; MWCO, molecular weight cutoff; BBB, blood-brain barrier; CSF, cerebrospinal fluid; HPLC, high-performance liquid chromatography; AUC, area under concentration-time curve.
under steady-state and nonsteady-state conditions. Brain ECF concentrations were compared with CSF and muscle ECF zidovudine concentrations. To assess the accuracy of the microdialysis sampling technique, free zidovudine concentrations were also measured in blood simultaneously by microdialysis and conventional serum sampling followed by ultrafiltration of the serum sample.

Materials and Methods

Animals. Adult male rhesus monkeys (Macaca mulatta), ranging in weight from 8.3 to 12.8 kg, were fed Purina Monkey Chow (Purina, St. Louis, MO) twice daily and were group housed in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996). This study was approved by the National Cancer Institute Institutional Animal Care and Use Committee.

Drug Formulation and Administration. Zidovudine for intravenous infusion (GlaxoSmithKline, Uxbridge, Middlesex, UK; 10 mg/ml; molecular mass, 267 Da) was diluted with 5% dextrose to a final concentration of 4 mg/ml and infused i.v. For steady-state experiments (animals B9078, 15398, H127, D28, and H351), a 5-mg/kg loading dose was administered as an i.v. bolus, followed by a 15-mg/kg/h continuous i.v. infusion. Before conducting microdialysis sampling, this infusion schedule was administered to two animals (B9884 and B9078) and standard serum and CSF sampling was performed during the infusion to determine when steady-state concentrations are achieved in serum and CSF. For bolus experiments (animals 85Z, H1090, and 9SL), 50 to 80 mg/kg was administered intravenously over 15 min. Zidovudine was infused through surgically implanted access ports that were attached to catheters in the jugular vein or through temporary peripheral intravenous catheters that were inserted before the experiment. Infusion rates were controlled with an AIM infusion pump (Abbott Laboratories, North Chicago, IL).

Conventional Blood, CSF, and Tissue Samples. For serum sampling, catheters were surgically placed into the saphenous or femoral vein and attached to a subcutaneously implanted access port (vascular access port; Access Technology, Skokie IL). On the day of the microdialysis procedure, animals without vascular access ports had a peripheral intravenous catheter inserted into a vein distant from the site of zidovudine infusion. Blood samples were collected into serum separator tubes (BD Biosciences, Rutherford, NJ). After clot formation, serum was separated by centrifugation (1000 g; 70 °C) and stored at −70 °C before analysis. Serum ultrafiltrate, which contained nonprotein-bound zidovudine, was prepared using Microcon centrifugal filter devices with MWCO 10,000 Da (Amicon YM-10; Millipore, Bedford, MA). Zidovudine protein binding in serum was 10 to 13%, similar to results published previously in rhesus monkeys (Collins et al., 1988).

Drug Formulation and Administration. Zidovudine for intra-venous infusion (GlaxoSmithKline, Uxbridge, Middlesex, UK; 10 mg/ml; molecular mass, 267 Da) was diluted with 5% dextrose to a final concentration of 4 mg/ml and infused i.v. For steady-state experiments (animals B9078, 15398, H127, D28, and H351), a 5-mg/kg loading dose was administered as an i.v. bolus, followed by a 15-mg/kg/h continuous i.v. infusion. Before conducting microdialysis sampling, this infusion schedule was administered to two animals (B9884 and B9078) and standard serum and CSF sampling was performed during the infusion to determine when steady-state concentrations are achieved in serum and CSF. For bolus experiments (animals 85Z, H1090, and 9SL), 50 to 80 mg/kg was administered intravenously over 15 min. Zidovudine was infused through surgically implanted access ports that were attached to catheters in the jugular vein or through temporary peripheral intravenous catheters that were inserted before the experiment. Infusion rates were controlled with an AIM infusion pump (Abbott Laboratories, North Chicago, IL).

Conventional Blood, CSF, and Tissue Samples. For serum sampling, catheters were surgically placed into the saphenous or femoral vein and attached to a subcutaneously implanted access port (vascular access port; Access Technology, Skokie IL). On the day of the microdialysis procedure, animals without vascular access ports had a peripheral intravenous catheter inserted into a vein distant from the site of zidovudine infusion. Blood samples were collected into serum separator tubes (BD Biosciences, Rutherford, NJ). After clot formation, serum was separated by centrifugation (1000 g for 15 min) and stored at −70 °C before analysis. Serum ultrafiltrate, which contained nonprotein-bound zidovudine, was prepared using Microcon centrifugal filter devices with MWCO 10,000 Da (Amicon YM-10; Millipore, Bedford, MA). Zidovudine protein binding in serum was 10 to 13%, similar to results published previously in rhesus monkeys (Collins et al., 1988).

For CSF sampling, four animals (B9884, B9078, 15398, and 85Z) had silicone Pudenz catheters surgically placed into the fourth ventricle and attached to a subcutaneously implanted Ommaya reservoir, as described previously (McCully et al., 1990). Lumbar CSF samples were obtained from temporary lumbar catheters in three animals (H127, D28, and H351). Cerebrospinal fluid was sampled from the subarachnoid space in two animals (H1090 and 9SL) (Bacher et al., 1994). All CSF samples were stored at −70 °C before analysis.

Six excisional muscle biopsies (0.77–2.57 g) were obtained from the right hind limb of 85Z after a bolus dose of zidovudine. Muscle biopsies were obtained before drug administration and at 0.25 (end of infusion), 1.25, 2.27, 3.27, and 4.3 h after administration of the zidovudine bolus. Excess blood was blotted from the specimens and they were immediately frozen on dry ice. Specimens were stored at −70 °C until processed and analyzed. Before high-performance liquid chromatography (HPLC) analysis, samples were thawed and homogenized using a glass Dounce and centrifuged at 1000g for 15 min at 4°C.
4°C. Using 500-μl aliquots of the supernatant, ultrafiltrates were prepared as described for serum specimens.

**Microdialysis Equipment.** CMA 102 microdialysis dual syringe pumps, Exnire 2.5-ml gastight syringes, CMA 20 vascular microdialysis probes (10-× 0.5-mm polycarbonate membrane MWCO 20,000; shaft length, 14 mm) with peel away split introducers, CMA 110 manual liquid switch, FEP tubing (1.2 μl/100 mm) and tubing adapters, and CMA 130 in vitro stand and probe clips were obtained from CMA/Microdialysis (North Chelmsford, MA). Equipment and probes were ethylene oxide gas-sterilized before use.

**Surgical Procedure.** Anesthesia was maintained by inhalation of isoflurane (1 to 2%) and oxygen during the surgical and sampling procedures (approximately 6 h). Buprenorphine and ketoprofen were administered for analgesia. Intravenous hydration (normal saline 10 ml/ kg/h) was maintained throughout the microdialysis procedure. Animals were positioned in ventral recumbency on the surgery table and their heads were placed in a stereotaxic unit (David Kopf Instruments, Tujunga, CA) using the eyebars and mouthpiece to position the head in a horizontal plane. The surgical area was clipped, scrubbed, and draped for aseptic surgery. A 4- to 5-cm midline incision was made over the frontal and anterior parietal bone. The periosteum was incised and retracted laterally along with the right temporalis muscle. Approximately 5 to 7 mm from the midline a 4-mm burr hole was created in the right temporal bone. A small dural incision permitted insertion of the microdialysis probe without damaging the probe membrane. The microdialysis probe was lowered into the cerebral cortex using the stereotaxic carrier. No guide probe was used. The top of the probe membrane was positioned 3 mm below the surface of the brain and extended 13 mm into the brain parenchyma. A second microdialysis probe was inserted into the left temporalis muscle by means of a peel away plastic introducer (CMA/Microdialysis). The probe was sutured to the temporalis muscle to prevent movement during the sampling procedures. A third microdialysis probe was percutaneously placed either in the cephalic or saphenous vein using a peel away plastic introducer over a 19-gauge needle. This probe was also sutured in place. When sampling was complete all microdialysis probes were removed, and the animal was recovered from anesthesia. Buprenorphine and ketoprofen were administered for analgesia, dexamethasone was administered for 3 days, and gentamicin and penicillin G with procaine were administered for 7 days after the procedure.

**Microdialysis.** For the continuous infusion experiments, the loading dose of zidovudine was administered and the infusion started before placement of the microdialysis probes in the brain, muscle, and blood to ensure that sampling was performed at steady state. To lessen the impact of the acute effects of probe insertion on tissue, microdialysis sampling began at least 20 min after probe insertion. Steady-state tissue ECF zidovudine concentration and recovery were determined using the zero net flux method (Wang et al., 1993) in vivo. In vitro recovery was also determined after completion of microdialysis sampling in the animal to verify probe membrane integrity. For all ZNF experiments the microdialysis probe perfusate flow rate was 1 μl/min and the probe membrane length was 10 mm.

The point of zero net flux was determined by sequentially perfusing four to five solutions with varying zidovudine concentrations into the microdialysis probe and measuring the zidovudine concentration in the outflow dialysate. With each perfusate zidovudine concentration, a 10-min equilibration period was followed by a collection time of 20 min (20 μl of dialysate). Plotting the difference between the inflow perfusate zidovudine concentration and the outflow dialysate zidovudine concentration as a function of the perfusate concentration resulted in a line with the slope equal to the relative recovery and an x-intercept equal to the steady-state tissue ECF zidovudine concentration. The perfusate zidovudine concentrations ranged from 0 to 50 μM for the brain probe and 0 to 500 μM for muscle and venous blood probes. In vitro recovery was determined by submerging the probe into 10 ml of continuously stirred physiological solution (Elliott’s B or lactated Ringers) maintained at 38°C. This solution represents the in vitro ECF. The brain microdialysis probe was sequentially perfused with 0, 1, 5, 10, and 25 μM [14C]zidovudine (Moravek, specific activity 55 mCi/mmol) and the in vitro ECF contained 5 μM [14C]zidovudine in Elliott’s B solution. Muscle and blood microdialysis perfusates contained 0 to 100 μM [14C]zidovudine and 20 μM [14C]zidovudine in lactated Ringers solution as the ECF.

For the bolus zidovudine experiments, retrodialysis (Wang et al., 1993) was used to estimate recovery. The perfusate flow rate was 0.5 μl/min and the probe membrane length was 10 mm. In vivo retrodialysis was performed before administration of the drug as a single 30-min collection after an equilibration period of at least 20 min. The retrodialysis perfusate contained 20 μM zidovudine. The zidovudine concentration was measured in the perfusate (perfusate) and the dialysate from the outflow tube (dialysate). Recovery was calculated from the following equation:

$$\text{Recovery} = \frac{\text{perfusate} - \text{dialysate}}{\text{perfusate}}$$

After completion of the retrodialysis collection, each microdialysis probe was equilibrated with drug-free solution (Elliott’s B solution for the brain probe and lactated Ringer’s solution for the muscle and blood probes). For monkey 85Z (bolus experiment), a single microdialysis sample was collected over the 4.3-h sampling period. For monkeys H909 and 9SL, microdialysis samples were obtained at hourly intervals (30 μl) starting with the initiation of the 15-min bolus infusion and continuing for 4 h. Microdialysis samples were stored at −70°C until analyzed. Tissue ECF zidovudine concentration was calculated by dividing the measured dialysate concentration by the retrodialysis-determined recovery. Serum and CSF samples were collected at the midpoint of each microdialysis collection period. As with the zero net flux method, the in vivo estimates of recovery by retrodialysis were used to calculate tissue ECF drug concentration.

For in vitro retrodialysis with the brain microdialysis probe, the perfusate contained 5 μM [14C]zidovudine, and well stirred Elliott’s B at 38°C was the in vitro ECF. The muscle and blood probes were perfused with 20 μM [14C]zidovudine, and well stirred lactated Ringer’s solution at 38°C was the in vitro ECF. Radioactivity in the perfusate and dialysates was measured using a liquid scintillation counter (model LS 3801; Beckman Coulter, Inc., Fullerton, CA).

**Zidovudine Assay.** Serum and CSF zidovudine concentrations were measured by a commercially available enzyme-linked immunosorbent assay method (Sigma-Aldrich, St. Louis, MO) for samples from the preliminary zidovudine infusions conducted to establish the time required to achieve steady state with the loading dose and continuous infusion schedule. All other samples were assayed with a previously reported reverse phase HPLC method (Kleckner et al., 1987), which was modified to accommodate the reduced volume of microdialysis samples. All serum and muscle biopsy samples were ultrafiltered as described above. CSF and microdialysis samples were not filtered or extracted. All samples were analyzed in triplicate.

The HPLC system consisted of a Sphero-5 RP-18, 5 μM, 30–× 2.1-mm guard column (Brownlee Columns, PerkinElmer Instruments, Norwalk, CT) coupled with a Nova Pak C18, 60 Å, 4 μM, 2–× 150-mm analytical column (Waters, Milford, MA) and a Waters model 2690 separations module. The mobile phase consisted of 90% 10 mM sodium acetate, pH 6.55, and 10% acetonitrile. Elution of zidovudine was achieved with isocratic flow at 0.5 ml/min. Analysis cycle time was 15 min. Eluant was monitored with a Waters 996 photo diode array detector at 267 nm. The retention time of zidovudine was approximately 4.5 min. The major metabolite of zidovudine, 3’-azido-3’-deoxythymidine-β-D-glucuronide, had a retention time of approximately 1 min.

The lower limit of detection was 0.1 μM and the lower limit of quantification was 0.25 μM. The intraday coefficient of variation was <8% for 0.5 μM, <2% for 10 μM, and <1% for 100 μM. The interday...
Pharmacokinetic Analysis. A two-compartment open model consisting of central and peripheral compartments with a first order elimination from the central compartment was fit to the serum concentration-time data from the individual bolus zidovudine experiments (85Z, H090, and 9SL). Four model parameters \( V_c \), volume of the central compartment; \( k_{el} \), first order elimination rate constant; and \( k_{cp} \) and \( k_{pc} \), first order exchange rate constants describing the movement of drug between the central (c) and peripheral (p) compartments were estimated with a weighted (EWT function) fit using MLAB (Civilized Software, Bethesda, MD). Clearance, volume of distribution at steady state, and half-lives were derived from the model parameters. For the continuous infusion experiments, free drug clearance was calculated from the infusion rate divided by the serum ultrafiltrate steady-state concentration. Area under the curve, in vivo in vitro, was calculated during the continuous zidovudine infusion. The central nervous system penetration after the bolus dose was calculated from the ratio of steady-state CSF and serum zidovudine concentration for microdialysis sampling during the continuous zidovudine infusion. The central nervous system penetration after the bolus dose was calculated from the CSF AUC/serum AUC for conventional sampling or brain AUC/blood AUC for microdialysis sampling.

Results

Recovery. The recovery (Table 1) for each microdialysis probe was estimated in vivo by the zero net flux method during the continuous infusions or by the retrodialysis method before the bolus doses. In vitro recovery was estimated by the same method after the in vivo portion of the experiment was completed to assess the integrity of the dialysis membrane. Microdialysis probe membrane length was 10 mm in all experiments. Recovery measured in vivo was substantially lower than in vitro recovery in the same probe. In vivo recovery was also tissue-dependent (highest in blood and lowest in brain), and in vivo recovery was more variable (higher coefficient of variation) than in vitro recovery across experiments. In vivo recovery was less variable with the retrodialysis method using a lower probe perfusate flow rate (0.5 \( \mu l/min \)).

Steady-State Experiments. When administered as a loading dose (5 mg/kg) followed by a continuous infusion (15 mg/kg/h), steady-state zidovudine concentrations were achieved within 1 h in serum and by 2 h in the CSF (Fig. 2). Steady-state zidovudine concentrations in two animals were 52 and 63 \( \mu M \) in serum and 5.3 and 4.6 \( \mu M \) in CSF. In subsequent microdialysis experiments, sampling was initiated more than 2 h after the loading dose and start of the continuous infusion.

The steady-state tissue zidovudine concentrations determined by microdialysis and using the zero net flux recovery method for each animal \( (n=5) \) are presented in Table 2 along with the results from conventional serum ultrafiltrate and CSF sampling. Blood zidovudine concentration measured in microdialysis samples from a vein was higher than free drug concentrations in serum ultrafiltrates by a median of 39%. The mean steady-state serum ultrafiltrate zidovudine concentration was 81.2 \( \mu M \), and the mean steady-state blood zidovudine concentration from microdialysis samples was 112 \( \mu M \). The mean (±S.D.) free zidovudine clearance based on the steady-state serum concentrations was 0.80 ± 0.28 l/h/kg. Steady-state zidovudine concentration in muscle (mean, 105 \( \mu M \)) measured by microdialysis was equivalent to the microdialysis estimate of steady-state blood zidovudine concentration. Brain steady-state zidovudine concentration (mean, 13.8 \( \mu M \)) from the microdialysis measurements was substantially lower than blood and muscle steady-state drug concentrations, indicating that the blood-brain barrier was functioning during the microdialysis collection period.

Brain steady-state zidovudine concentrations from the microdialysis samples were similar to conventional CSF measurements (Table 2). In animal H127, the CSF zidovudine concentration and the CSF/serum ratio were substantially higher than in the other four animals and the two pilot animals in which the time to reach steady state was determined. Excluding animal H127, the mean brain steady-state zidovudine concentration \( (n=4) \) was 14.3 \( \mu M \) and the mean CSF steady-state zidovudine concentration was 14.1 \( \mu M \). The brain/blood ratio from the microdialysis measurements without animal H127 was 0.12 and the CSF/serum ultrafiltrate ratio was 0.17.

Bolus Dose Experiments. The serum ultrafiltrate zidovudine concentrations were well described by the two-compartment model (Fig. 3). The fitted and derived pharma-

### Table 1

Comparison of microdialysis probe recovery measured in vivo and in vitro by the zero net flux method for the continuous zidovudine infusion studies and by the retrodialysis method for the bolus zidovudine studies

<table>
<thead>
<tr>
<th>Method</th>
<th>Flow Rate</th>
<th>n</th>
<th>Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>( \mu l/min )</td>
<td></td>
<td>Blood</td>
</tr>
<tr>
<td>Zero net flux</td>
<td>1</td>
<td>5</td>
<td>Mean 0.79</td>
</tr>
<tr>
<td></td>
<td>S.D.</td>
<td></td>
<td>0.11</td>
</tr>
<tr>
<td></td>
<td>CV %</td>
<td></td>
<td>14</td>
</tr>
<tr>
<td>Retrodialysis</td>
<td>0.5</td>
<td>3</td>
<td>Mean 0.90</td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td></td>
<td>0.07</td>
</tr>
<tr>
<td></td>
<td>CV %</td>
<td></td>
<td>8</td>
</tr>
</tbody>
</table>

CV, coefficient of variation.
* \( n = 4 \), the outflow tube on one probe was damaged during probe removal from the brain after completion of the in vivo experiment.
The brain ECF penetration based on microdialysis tissue sampling was similar at steady state (mean, 0.13) and after the bolus dose (mean, 0.18) and similar to the CSF penetration at steady state with the outlier excluded.

Although the brain ECF and CSF penetration was similar based on the 0- to 4-h AUC values, there seem to have been differences in the concentration-time profiles during these transient experiments (Fig. 3, C, F, and I). The mean shape of the CSF profiles obtained by sampling from the subarachnoid space in two animals (H090 and 9SL) exhibited a rapid elevated peak. This contrasted with the broad time profile from the corresponding brain ECF mean profile from hourly microdialysis sampling in the same animals. A similar broad time profile was found in the ventricular CSF of the third animal (85Z). The difference between the subarachnoid and ventricular CSF results suggests a possible lack of equivalence in the transient response at these CSF sampling sites.

Truncating the AUC after 4 h represents an approximation. As noted above, the zidovudine time profiles displayed in Fig. 3C for the CSF of animal 85Z and the ECF microdialysis of animals H090 and 9SL are relatively slow. As a consequence, these 0- to 4-h AUC values probably underestimate the complete zero to infinity AUC values to a greater degree than in the more rapidly responding blood, serum, and muscle compartments of Fig. 3. The corresponding ECF and CSF penetration values in Table 4 may likewise be somewhat underestimated.

Toxicity. The microdialysis sampling was well tolerated. Animal D28, which received continuous infusion zidovudine, had a transient elevation in liver transaminases, elevated serum creatine kinase, and a single episode of hemoglobinuria after the procedure. These laboratory abnormalities were accompanied by anorexia and lassitude. These signs and symptoms were attributed to zidovudine and resolved with supportive care measures. Two animals that received bolus dosing of zidovudine were sacrificed. The euthanasia of 85Z (the animal from which the muscle biopsy specimens were obtained) was planned. H090 was euthanized 27 h after the completion of the microdialysis sampling period for multisystem organ failure. H090 recovered from anesthesia but had progressive deterioration in cardiac, respiratory, and renal function. At necropsy, a previously undiagnosed chronic cardiomyopathy was discovered. There was no evidence of hemorrhagic or ischemic changes at the site of microdialysis probe insertion in the brain. Both 85Z and H090 received 80-mg/kg i.v. bolus of zidovudine. The third animal in the bolus group (9SL) received 50 mg/kg i.v. zidovudine and tolerated the procedure well.

Discussion

Microdialysis is a minimally invasive sampling technique that can be used to continuously monitor drug concentrations in the ECF of tissues that are accessible to microdialysis probe placement. The free drug concentration at the site of drug action in tissues is a critical determinant of the intensity of the drug’s effect, and therefore monitoring tissue free drug concentration may be more informative than monitoring plasma drug concentrations.

We compared microdialysis sampling from blood and tissues to conventional sampling methods in a nonhuman primate model at steady state during a continuous infusion of

![Graph](image-url)
Recovery was determined by the zero net flux method (Table 1). CSF/serum and brain/blood ratios represent the ratio of the steady state zidovudine concentrations at the designated sampling sites.

<table>
<thead>
<tr>
<th>Animal</th>
<th>Serum (µM)</th>
<th>Blood (µM)</th>
<th>Muscle (µM)</th>
<th>CSF (µM)</th>
<th>Brain (µM)</th>
<th>CSF/serum</th>
<th>Brain/Blood (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B9078</td>
<td>62.9</td>
<td>123</td>
<td>90.1</td>
<td>12.9</td>
<td>4.5</td>
<td>0.20</td>
<td>0.04</td>
</tr>
<tr>
<td>I5398</td>
<td>48.5</td>
<td>58.3</td>
<td>85.3</td>
<td>8.1</td>
<td>9.9</td>
<td>0.17</td>
<td>0.17</td>
</tr>
<tr>
<td>H127</td>
<td>73.6</td>
<td>66.8</td>
<td>94.4</td>
<td>50.1</td>
<td>11.9</td>
<td>0.69</td>
<td>0.18</td>
</tr>
<tr>
<td>D28</td>
<td>151</td>
<td>217</td>
<td>193</td>
<td>25.7</td>
<td>31.6</td>
<td>0.17</td>
<td>0.16</td>
</tr>
<tr>
<td>H351</td>
<td>70.1</td>
<td>97.5</td>
<td>60.5</td>
<td>9.7</td>
<td>11</td>
<td>0.14</td>
<td>0.11</td>
</tr>
<tr>
<td>Mean</td>
<td>81.2</td>
<td>112</td>
<td>105</td>
<td>21.3</td>
<td>13.8</td>
<td>0.27</td>
<td>0.13</td>
</tr>
<tr>
<td>S.D.</td>
<td>40.2</td>
<td>63.8</td>
<td>51.1</td>
<td>17.5</td>
<td>10.4</td>
<td>0.23</td>
<td>0.06</td>
</tr>
<tr>
<td>CV (%)</td>
<td>49.5</td>
<td>56.7</td>
<td>48.8</td>
<td>82.3</td>
<td>56.7</td>
<td>85.2</td>
<td>44</td>
</tr>
</tbody>
</table>

CV, coefficient of variation.

* Excluding the CSF and CSF/serum values for animal H127, which was an outlier (see text), the mean steady state CSF zidovudine concentration is 14.1 µM and the CSF/serum ratio is 0.17.
Fig. 3. Comparison of conventional serum and CSF zidovudine concentration profiles with microdialysis measurements in blood, muscle, and brain in each animal (85Z, H090, and 9SL) after a bolus dose of zidovudine. 85Z and H090 received 80 mg/kg zidovudine, and 9SL received 50 mg/kg. A, compares serum ultrafiltrate zidovudine concentrations (open circles) with blood microdialysis concentration (bar) in animal 85Z. All microdialysis samples for 85Z were collected over a single 4-h interval. The line represents the two-compartment model fit to the serum concentration-time data. B, compares the simulated zidovudine concentration in the peripheral compartment of the two-compartment model (solid line) with the muscle biopsies (open squares) and muscle microdialysis concentration (bar) in 85Z. C, compares zidovudine concentrations in the CSF with the brain microdialysis concentration (bar) in 85Z. The closed triangles denote the intraventricular CSF concentrations in animal 85Z. D, compares serum ultrafiltrate zidovudine concentrations (open circles) with blood microdialysis concentrations (bars) in animal 9SL. All microdialysis samples from 9SL were obtained over 1-h intervals for 4 h. The line represents the two-compartment model fit to the serum concentration-time data. E, compares the simulated zidovudine concentration in the peripheral compartment of the two-compartment model (solid line) with muscle microdialysis concentrations (bars) in animal 9SL. F, compares zidovudine concentrations in the CSF to the brain microdialysis concentrations in 9SL. The open triangles present the CSF means in the subarachnoid space of animal 9SL and the solid bars indicate the ECF means in 1-h microdialysis samples. G, compares serum ultrafiltrate zidovudine concentrations (open circles) with blood microdialysis concentrations (bars) in animal H090. All microdialysis samples from H090 were obtained over 1-h intervals for 4 h. The line represents the two-compartment model fit to the serum concentration-time data. H, compares the simulated zidovudine concentration in the peripheral compartment of the two-compartment model (solid line) with muscle microdialysis concentrations (bars) in animal H090. I, compares zidovudine concentrations in the CSF with the brain microdialysis concentrations in H090. The open triangles present the CSF means in the subarachnoid space of animal H090 and the solid bars indicate the ECF means in 1-h microdialysis samples.
able estimate of muscle drug exposure for zidovudine. The
AUC in muscle derived from serial muscle biopsies over 4 h in
a single animal was lower than the microdialysis estimate of
muscle ECF zidovudine AUC, but these methods measure
drug concentrations in different compartments within the
tissue. The homogenized muscle biopsy specimens represent
an average of extracellular, intracellular, and intravascular
drug concentrations within the tissue, whereas the microdi-
lalysis samples specifically measure free ECF drug concen-
tration.

From pharmacokinetic theory the equilibrium free concen-
tration of a solute in a noneliminating compartment should
be equal to the free concentration in the blood or plasma; the
same identity holds for the AUC from zero to infinity. These
predictions are consistent with the results of this research in
which the muscle microdialysis, blood microdialysis, and se-
rial muscle biopsies specifically measure free ECF drug concen-
tration, which is to tightly regulate the composition of brain
extracellular fluid and CSF, respectively, is similar. Under
both steady-state conditions and transient conditions, the
zidovudine concentration in the CSF and brain ECF were
comparable, and the CSF/serum ultrafiltrate and brain/blood
ratios were similar if one outlier is excluded. The limited
penetration of zidovudine in rhesus brain presumably results
from active transport mechanisms similar to those that have
been shown to restrict brain penetration of zidovudine in
other species (Dykstra et al., 1993; Wang et al., 1997).

References
Adamson PC, Balis FM, Arndt CA, Holcenberg JS, Narang PK, Murphy RF, Gillespie
AJ, and Poplack DG (1991) Intrathecal 6-mercaptopurine: preclinical pharmaco-
Bacher JD, Balis FM, McCully CL, and Godwin KS (1994) Cerebral subarachnoid
Balis FM, Pizzo PA, Murphy RF, Eddy J, Jarosinski PF, Falloon J, Broder S, and
Poplack DG (1989) The pharmacokinetics of zidovudine administered by continu-
Benveniste H and Huttemeier PC (1990) Microdialysis theory and application. Prog
administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol

### Table 3
Pharmacokinetic parameters derived from fitting a two-compartment model with first order elimination from the central compartment to the serum ultrafiltrate zidovudine concentration-time data after the bolus dose in three animals

<table>
<thead>
<tr>
<th>Animal</th>
<th>Model Parameters</th>
<th>Derived Parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>( V_c ) (l/kg)</td>
<td>( k_{ael} ) (h(^{-1}))</td>
</tr>
<tr>
<td>85Z</td>
<td>0.13</td>
<td>4.7</td>
</tr>
<tr>
<td>H909</td>
<td>0.43</td>
<td>1.1</td>
</tr>
<tr>
<td>9SL</td>
<td>0.48</td>
<td>1.6</td>
</tr>
<tr>
<td>Mean</td>
<td>0.35</td>
<td>2.5</td>
</tr>
<tr>
<td>S.D.</td>
<td>0.19</td>
<td>2.2</td>
</tr>
<tr>
<td>CV (%)</td>
<td>55</td>
<td>78</td>
</tr>
</tbody>
</table>

CV, coefficient of variation.

### Table 4
AUCs in serum ultrafiltrate and CSF collected by conventional methods and in blood, muscle, and brain collected by microdialysis (µD) after a bolus dose of 50 or 80 mg/kg

<table>
<thead>
<tr>
<th>Animal</th>
<th>Zidovudine AUC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Serum (µM·h)</td>
</tr>
<tr>
<td>85Z</td>
<td>490</td>
</tr>
<tr>
<td>H909</td>
<td>486</td>
</tr>
<tr>
<td>9SL</td>
<td>363</td>
</tr>
<tr>
<td>Mean</td>
<td>446</td>
</tr>
<tr>
<td>S.D.</td>
<td>72</td>
</tr>
<tr>
<td>CV (%)</td>
<td>16.2</td>
</tr>
</tbody>
</table>

CV, coefficient of variation.

a Zidovudine AUC in muscle derived from multiple muscle biopsies was 335 µM · h.

b Animal 9SL received a bolus dose of 50 mg/kg; AUCs in this animal were normalized to a dose of 80 mg/kg.


Address correspondence to: Elizabeth Fox, Pharmacology and Experimental Therapeutics Section Pediatric Oncology Branch, National Cancer Institute, 10/13C103, 10 Center Dr., MSC 1920, Bethesda, MD 20892-1920. E-mail: foxb@mail.nih.gov